Self-Exams vs. Professional Clinical Screening

There is a real difference between a formal self-examination performed on a schedule as a screening method, and simply knowing your own body well enough to notice when something changes.

Organized guidance has moved away from the first. It has not moved away from the second. Nothing below is an argument for paying less attention to yourself.

Formal breast self-examination was taught for decades as a monthly routine. It was then tested in randomized trials, including one in Shanghai and one in Russia. The National Cancer Institute's summary of that evidence is direct: breast self-examination has been compared with no screening and has been shown to have no benefit in reducing breast cancer mortality.

The trials also found a cost. NCI states that instruction in formal breast self-examination leads to more breast biopsies and more diagnoses of benign breast lesions. In the trial data cited, the biopsy rate was 1.8 percent among women in the self-examination group compared with 1.0 percent in the control group. More women had procedures to investigate lumps that were not cancer, and no fewer women died of breast cancer.

That combination, no lives saved and more procedures, is why formal breast self-examination is no longer recommended as a screening method. NCI puts it plainly: breast self-exams are not an adequate breast cancer screening test on their own. The same summary notes that a clinical breast exam is not an adequate screening test by itself either.

The American Cancer Society reaches the same conclusion, saying research has not shown a clear benefit of regular physical breast exams done by either a health professional or by women themselves.

Both organizations are just as clear about the other half of this.

The American Cancer Society states that women should be familiar with how their breasts normally look and feel, and should report any changes to a health care provider right away. NCI says it is important for all women to be aware of how their breasts normally feel so that they can check with their doctors about any unusual changes.

This is usually called breast self-awareness. It has no schedule and no technique to get right. It is the baseline familiarity that makes a change noticeable: a new lump, a change in shape or skin texture, a nipple change or discharge, or anything new for you.

Dropping the monthly ritual is not the same as ignoring your body. The evidence went against the ritual, not against noticing.

Testicular self-examination is widely taught, and the evidence behind it is genuinely limited.

NCI states there is no standard or routine screening test used for early detection of testicular cancer, and that no studies have been done to find out whether testicular self-exams, regular exams by a doctor, or other screening tests in men with no symptoms would decrease the risk of dying from the disease.

The US Preventive Services Task Force went further, recommending against screening for testicular cancer in adolescent or adult men. It is a grade D statement covering both self-examination and clinician examination, issued in 2011. Its reasoning: the disease is uncommon, at roughly 5.4 cases per 100,000 males a year, more than 90 percent of newly diagnosed cases are cured, and most cases are already found incidentally. The Task Force concluded with moderate certainty that screening for testicular cancer has no net benefit.

None of that means a new lump, swelling, heaviness or change in a testicle should be left alone. It means the evidence does not support running a formal screening program in a situation where outcomes are already good and most tumors come to attention without one.

Skin is the one place where you can look directly at the tissue in question, and the guidance reflects that.

The American Cancer Society describes how to do a skin self-exam: in a well-lit room, with a full-length mirror and a hand-held mirror, checking the whole body, including the scalp, back, buttocks, genital area, between fingers and toes, and the soles of the feet. It says doing one about once a month is usually suggested, with the right frequency depending on individual risk.

For moles and marks, the American Cancer Society sets out the ABCDE rule:

• A, asymmetry. One half of a mole or birthmark does not match the other.
• B, border. The edges are irregular, ragged, notched or blurred.
• C, color. The color is not the same all over, and may include different shades of brown or black, sometimes with patches of pink, red, white or blue.
• D, diameter. The spot is larger than 6 millimeters across, about the size of a pencil eraser.
• E, evolving. The mole is changing in size, shape or color.

Alongside it is the ugly duckling sign: a spot that looks noticeably different from all your other moles. Other warning signs include a sore that does not heal, pigment spreading past the edge of a mole, redness or swelling beyond the border, new itching, tenderness or pain, and surface changes such as scaliness, oozing, bleeding or a lump.

On whole-body visual skin examination performed by a clinician as a screening test in people without symptoms, the Task Force issued an I statement in April 2023, meaning the evidence is insufficient to weigh benefits against harms. An I statement is not a recommendation against. It also does not apply to people who have symptoms or a suspicious lesion, who are evaluated regardless. NCI similarly notes that skin exams have not been shown to decrease the risk of dying from skin cancer.

Across all three, the same line separates the two ideas.

A screening ritual is performed on a schedule, on the assumption that the searching itself finds disease earlier. For breast tissue that assumption was tested directly and did not hold.

Noticing and reporting change rests on a different basis: you are the only person who sees your body every day, and a change you can describe accurately gives a clinician something concrete to work with. That part has never been in question.

So if something is new, persistent, or different from your normal, describe it: what it is, where it is, how long it has been there, and whether it is changing. What happens after that is a clinical judgement, and it does not wait for a screening schedule.